| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.041 | 0.8 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.043 | 0.8 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |